IP Library › Assignment 061447/0760
Patent Assignment
Reel/Frame 061447/0760

Assignment of Assignor's Interest

Recorded: 2022-09-15 Pages: 47
Assignor
Assignee
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA-SHI, 541-0045, JAPAN
Covered Properties (42)
Diagnosis and Treatment of Multiple Sulfatase Deficiency and Other Sulfatase Deficiencies
Methods and Compositions for Cns Delivery of Heparan N-Sulfatase
Cns Delivery of Therapeutic Agents
Methods and Compositions for Cns Delivery of Iduronate-2-Sulfatase
Methods and Compositions for Cns Delivery of Arylsulfatase A
Treatment of Sanfilippo Syndrome Type B
Process for Purifying Heparan-N-Sulfatase
Biomarkers for Sanfilippo Syndrome and Uses Thereof
Stable Formulations for Cns Delivery of Arylsulfatase A
Treatment of Cognitive Impairment of Hunter Syndrome by Intrathecal Delivery of Iduronate-2-Sulfatase
Purification of Iduronate-2-Sulfatase
Cells for Producing Recombinant Iduronate-2-Sulfatase
Methods and Compositions for Intrathecally Administered Treatment of Mucupolysaccharidosis Type Iiia
Method of Characterizing Lysosomal Enzymes
A Cell That Expresses a Sulfatase and a Formylglycine Generating Enzyme
Patent: 8,227,212 →
Application: 10/775,678 →
Publication: US 2004/0229250
Methods and Compositions for Cns Delivery of Heparan N-Sulfatase
Patent: 9,320,711 →
Application: 13/168,957 →
Publication: US 2012/0014936
Cns Delivery of Therapeutic Agents
Patent: 9,283,181 →
Application: 13/168,961 →
Publication: US 2012/0003202
Methods and Compositions for Cns Delivery of Arylsulfatase A
Patent: 9,770,410 →
Application: 13/168,963 →
Publication: US 2012/0009171
Methods and Compositions for Cns Delivery of Iduronate-2-Sulfatase
Patent: 8,545,837 →
Application: 13/168,966 →
Publication: US 2011/0318323
Purification of Iduronate-2-Sulfatase
Patent: 9,051,556 →
Application: 13/829,706 →
Publication: US 2014/0004096
Cells for Producing Recombinant Iduronate-2-Sulfatase
Patent: 9,150,841 →
Application: 13/829,780 →
Publication: US 2014/0004593
Treatment of Sanfilippo Syndrome Type B by Intrathecal Administration of Alpha-N-Acetylglucosaminidase
Patent: 9,814,764 →
Application: 13/892,076 →
Publication: US 2013/0295077
Methods and Compositions for Cns Delivery of Iduronate-2-Sulfatase
Patent: 9,220,677 →
Application: 13/974,457 →
Publication: US 2014/0271598
Method of Analyzing the Charge Profile of Heparan N-Sulfatase
Patent: 9,290,793 →
Application: 14/210,058 →
Publication: US 2014/0294800
Methods and Compositions for Treatment of Hunter Syndrome
Patent: 9,492,511 →
Application: 14/673,607 →
Publication: US 2015/0313972
Cells for Producing Recombinant Iduronate-2-Sulfatase
Patent: 9,719,074 →
Application: 14/832,728 →
Publication: US 2016/0053238
Cns Delivery of Therapeutic Agents
Application: 15/016,141 →
Publication: US 2017/0042978
Characterization of Lysosomal Enzymes by Capillary Zone Electrophoresis
Application: 15/040,174 →
Publication: US 2016/0362719
Methods and Compositions for Treatment of Hunter Syndrome
Application: 15/279,018 →
Publication: US 2017/0073652
Methods and Compositions for Cns Delivery of Arylsulfatase A
Application: 15/684,568 →
Publication: US 2018/0071212
Therapeutic Fusion Protein Comprising an Alpha-N-Acetylglucosaminidase and a Lysosomal Targeting Moiety
Application: 15/715,748 →
Publication: US 2018/0085438
Treatment of Cognitive Impairment of Mucopolysaccharidosis Type IIIA by Intrathecal Delivery of Heparan N-Sulfatase
Application: 15/746,192 →
Publication: US 2018/0207242
Stable Formulations for Cns Delivery of Arylsulfatase A
Application: 16/000,557 →
Publication: US 2019/0125841
Methods and Compositions for Cns Delivery of Heparan N-Sulfatase
Application: 16/036,584 →
Publication: US 2019/0183984
Methods and Compositions for Cns Delivery of Iduronate-2-Sulfatase
Application: 16/515,568 →
Publication: US 2020/0046810
Cns Delivery of Therapeutic Agents
Application: 16/573,557 →
Publication: US 2020/0113981
Methods and Compositions for CNS Delivery of Arylsulfatase A
Application: 16/828,731 →
Publication: US 2020/0405825
Stable Formulations for Cns Delivery of Arylsulfatase A
Application: 16/851,822 →
Publication: US 2020/0237883
Compositions Comprising Iduronate-2-Sulfatase
Application: 17/092,034 →
Publication: US 2021/0317426
Methods and Compositions for Cns Delivery of Heparan N-Sulfatase
Application: 17/350,860 →
Publication: US 2022/0133862
Treatment of Sanfilippo Syndrome Type B
Application: 17/350,909 →
Publication: US 2022/0133863
Methods and Compositions for Cns Delivery of Iduronate-2-Sulfatase
Application: 17/578,119 →
Publication: US 2023/0026836
Related Assignments (17)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 30, 2006
From: VON FIGURA, KURT; SCHMIDT, BERNHARD; DIERKS, THOMAS; HEARTLEIN, MICHAL W.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 018583/0228 →
Assignment of Assignor's Interest Aug 30, 2011
From: ZHU, GAOZHONG; LOWE, KRIS; SHAHROKH, ZAHRA; CHRISTIAN, JAMES
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 026825/0422 →
Assignment of Assignor's Interest Aug 30, 2011
From: SALAMAT-MILLER, NAZILA; TAYLOR, KATHERINE; CAMPOLIETO, PAUL; SHAHROKH, ZAHRA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 026825/0460 →
Assignment of Assignor's Interest Sep 22, 2011
From: NATOLI, FARAH; ZHU, GAOZHONG; TEREW, JENNIFER; JIANG, YUAN
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 026949/0809 →
Assignment of Assignor's Interest Sep 22, 2011
From: CALIAS, PERICLES; PAN, JING; POWELL, JAN; CHARNAS, LAWRENCE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 026949/0964 →
Assignment of Assignor's Interest Sep 22, 2011
From: CONCINO, MICHAEL F.; CALIAS, PERICLES; PAN, JING; HOLMES, KEVIN
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 026949/0870 →
Assignment of Assignor's Interest Aug 31, 2012
From: NICHOLS, DAVID
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 028881/0303 →
Assignment of Assignor's Interest Jan 28, 2013
From: HASLETT, PATRICK; RICHARD, CHARLES W., III
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 029701/0793 →
Assignment of Assignor's Interest Mar 8, 2013
From: BARBIER, ANN; MCCAULEY, THOMAS; RICHARD, III, CHARLES W.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 029948/0947 →
Assignment of Assignor's Interest Apr 16, 2013
From: NICHOLS, DAVE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 030223/0038 →
Assignment of Assignor's Interest Apr 16, 2013
From: BOLDOG, FERENC; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 030223/0133 →
Assignment of Assignor's Interest Jul 26, 2013
From: CONCINO, MICHAEL F.; CALIAS, PERICLES; PAN, JING; HOLMES, KEVIN
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 030882/0744 →
Assignment of Assignor's Interest Nov 25, 2013
From: ZHU, GAOZHONG; LOWE, KRIS; SHAHROKH, ZAHRA; CHRISTIAN, JAMES
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 031666/0107 →
Assignment of Assignor's Interest Apr 15, 2014
From: HASLETT, PATRICK; BARBIER, ANN; CALIAS, PERICLES; PFEIFER, RICHARD
To: SHIRE HUMAN GENETIC THERAPIES, INC
Reel/Frame 032681/0167 →
Assignment of Assignor's Interest Aug 7, 2014
From: ROSEMAN, DANIEL S.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033487/0575 →
Assignment of Assignor's Interest Apr 7, 2015
From: NICHOLS, DAVE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035347/0147 →
Assignment of Assignor's Interest Sep 1, 2015
From: BOLDOG, FERENC; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 036465/0257 →